Pepvise
Compound profile· Compounds

KPV peptide, what the evidence shows

By The PepVise Editorial Team · Reviewed July 4, 2026 · 13 min read

Evidence Ledger for KPV (lysine-proline-valine): the C-terminal tripeptide fragment of the hormone alpha-MSH with anti-inflammatory effects in animal and cell models, no FDA-approved indication, and a very thin human evidence base.

We describe what has been measured, by whom, at what scale, with what effect size, and with what caveats. Hedging, here, is honesty.
The PepVise Editorial Teamfrom the house style guide
Editorial reference
Primary literature

PubMed saved search, 'KPV alpha-MSH tripeptide'

KPV is a compound where the search itself is the most honest starting point, because it surfaces a genuine, mostly preclinical literature on anti-inflammatory activity descended from alpha-MSH biology alongside the near-total absence of controlled human trials. A saved search separates the real cell biology from the marketing more honestly than any summary, including ours.

Reference reading

The texts we read alongside the papers.

  1. 01
    Primary literature

    PubMed saved search, 'KPV alpha-MSH tripeptide'

    A PubMed search surfaces the defining pattern: a real preclinical literature on KPV as the anti-inflammatory fragment of alpha-MSH, concentrated in cell culture and rodent models of gut and skin inflammation, alongside a near-total absence of controlled clinical trials in humans. It is the fastest way to separate what has actually been studied from what vendors claim.

  2. 02
    Reference text

    Williams Textbook of Endocrinology (14th ed.)

    KPV is the C-terminal tripeptide of alpha-MSH, a melanocortin peptide, and the underlying melanocortin and inflammation biology is standard science. Williams supplies the receptor and signaling biology needed to read the mechanistic claims critically, without the marketing layer that vendor and forum pages add. Read it for the physiology, not for use guidance.

  3. 03
    Popular-science background

    Outlive, Peter Attia, MD (with Bill Gifford)

    Attia's framework for separating a mechanistically plausible finding from a demonstrated clinical endpoint applies directly to KPV, whose strongest data sit in cell and animal models. It does not cover KPV; the reasoning discipline is the point.

Methodology

How we read the literature

Evidence tier
We grade the literature on four tiers, High (replicated RCTs or meta-analyses), Moderate (multiple trials with mixed findings), Low (a single pilot or case series), and Anecdotal (preclinical only, no human data). The tier appears on every compound profile beside the claim it supports.
Trial stage
Where a compound sits in the human development pipeline is recorded as Preclinical, Phase 1, Phase 2, or Phase 3+. We pull the current stage from ClinicalTrials.gov and the EU Clinical Trials Register on access date and re-verify quarterly.
Regulatory status
We state the FDA posture plainly, approved for indication X, or labeled for research use only, or removed from the 503A list, or investigational under a specific IND. Regulatory status changes; every post carries a review date.
Where we're uncertain
Every compound profile closes with a named uncertainty section, the question we can't answer from the current literature, the trial we'd want to see, the effect size we'd treat as a real signal. Uncertainty is not a failure mode here; it's load-bearing.
Frequently asked

The questions readers actually bring us.

Is KPV FDA-approved?
No. KPV has no FDA-approved indication and is not registered as a drug. It circulates as a research chemical labeled for non-human use. The anti-inflammatory claims come from preclinical studies, not from any approved human use.
What is KPV supposed to do?
It is the C-terminal tripeptide of alpha-MSH, studied as an anti-inflammatory agent. In cell culture and rodent models it reduces inflammatory signaling, including NF-kB activation, and has been tested in models of colitis, skin inflammation, and wound healing. Some work also reports antimicrobial activity. These are preclinical findings, not demonstrated human outcomes.
How strong is the human evidence for KPV?
Very thin. The evidence base is overwhelmingly cell-culture and animal work. There are no adequately powered, placebo-controlled human trials establishing that KPV treats any condition, and no FDA-approved use. Its effective dose and safety profile in people are unknown.
How is KPV related to alpha-MSH and to BPC-157?
KPV is literally a piece of alpha-MSH, its final three amino acids, which is where much of the parent hormone's anti-inflammatory activity resides. It is unrelated to BPC-157, which is a separate gastric-derived peptide framed around tissue repair; the two are sometimes discussed together only because both are marketed for gut and injury contexts on the strength of preclinical data.
Why does PepVise not give a KPV dose?
Because we describe the literature and do not recommend administration. The doses repeated online come from vendor pages and forums, not from replicated human dose-finding trials, and the human data are too thin to define a validated dose in the first place. We explain how these research chemicals are regulated separately.
What would change our reading

A Phase 2 randomized trial with blinded outcome assessment would change the reading. A new independent replication outside the currently dominant research group would change the reading. A regulatory action, approval, restriction, or a class warning, would change the reading. When any of those lands, we update this profile within a week and mark what changed.

The masthead

About The Pepvise Editorial Team

The Pepvise Editorial Team is a small group of researchers and science writers reading the peer-reviewed peptide literature and translating it into calm, cited analysis. We do not sell peptides, recommend peptides, or tell readers what to administer. We describe what has been measured, by whom, at what scale, with what effect size.

Compound reviews are signed off by Dr. Priya Narang, MD, MPH (endocrinologist) and Dr. Marcus Haley, PharmD, BCPS (board-certified clinical pharmacist). Both hold verifiable state-board licenses and have signed editorial-independence letters with us. See the full editorial board →

Further reading

Adjacent in the literature.

Compounds · Compound profile

BPC-157, What the Evidence Shows

Evidence Ledger for BPC-157: 50+ preclinical studies, 1 human pilot (Chang 2014, n=12), 1 active Phase trial, FDA removed from 503A list in 2023.

16 min readCompounds · Compound profile

TB-500, The Field Guide

TB-500 vs Thymosin Beta-4 (same compound), mechanism, the preclinical tendon and recovery literature, and where the human data is thin.

14 min readCompounds · Compound profile

GHK-Cu, Evidence and Hype

Copper peptide signaling, the topical RCT evidence for hair and skin, and the gap between topical and injectable claims.

13 min read

Get the 2026 Peptide Evidence Ledger.

A 12-page PDF summary of where 10 major compounds sit, Preclinical / Human pilot / Phase trial / FDA status. Updated quarterly. Free.

By subscribing, you agree to our Privacy Policy. One calm, cited email a week. Unsubscribe anytime.